BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 30416685)

  • 1. Antitumor profile of the PI3K inhibitor ZSTK474 in human sarcoma cell lines.
    Namatame N; Tamaki N; Yoshizawa Y; Okamura M; Nishimura Y; Yamazaki K; Tanaka M; Nakamura T; Semba K; Yamori T; Yaguchi SI; Dan S
    Oncotarget; 2018 Oct; 9(80):35141-35161. PubMed ID: 30416685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subtype-selective induction of apoptosis in translocation-related sarcoma cells induced by PUMA and BIM upon treatment with pan-PI3K inhibitors.
    Isoyama S; Tamaki N; Noguchi Y; Okamura M; Yoshimatsu Y; Kondo T; Suzuki T; Yaguchi SI; Dan S
    Cell Death Dis; 2023 Feb; 14(2):169. PubMed ID: 36849535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor.
    Yaguchi S; Fukui Y; Koshimizu I; Yoshimi H; Matsuno T; Gouda H; Hirono S; Yamazaki K; Yamori T
    J Natl Cancer Inst; 2006 Apr; 98(8):545-56. PubMed ID: 16622124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of SOX2 induces cell apoptosis and G1/S arrest in Ewing's sarcoma through the PI3K/Akt pathway.
    Ren C; Ren T; Yang K; Wang S; Bao X; Zhang F; Guo W
    J Exp Clin Cancer Res; 2016 Mar; 35():44. PubMed ID: 26969300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combinatorial strategies to potentiate the efficacy of HDAC inhibitors in fusion-positive sarcomas.
    Lanzi C; Cassinelli G
    Biochem Pharmacol; 2022 Apr; 198():114944. PubMed ID: 35152144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of PI3K by ZSTK474 suppressed tumor growth not via apoptosis but G0/G1 arrest.
    Dan S; Yoshimi H; Okamura M; Mukai Y; Yamori T
    Biochem Biophys Res Commun; 2009 Jan; 379(1):104-9. PubMed ID: 19094964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SS18-SSX fusion protein-induced Wnt/β-catenin signaling is a therapeutic target in synovial sarcoma.
    Trautmann M; Sievers E; Aretz S; Kindler D; Michels S; Friedrichs N; Renner M; Kirfel J; Steiner S; Huss S; Koch A; Penzel R; Larsson O; Kawai A; Tanaka S; Sonobe H; Waha A; Schirmacher P; Mechtersheimer G; Wardelmann E; Büttner R; Hartmann W
    Oncogene; 2014 Oct; 33(42):5006-16. PubMed ID: 24166495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiproliferative effect of ZSTK474 alone or in combination with chemotherapeutic drugs on HL60 and HL60/ADR cells.
    Zhou Q; Chen Y; Zhang L; Zhong Y; Zhang Z; Wang R; Jin M; Gong M; Qiu Y; Kong D
    Oncotarget; 2017 Jun; 8(24):39064-39076. PubMed ID: 28388564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor identified using the JFCR39 drug discovery system.
    Kong DX; Yamori T
    Acta Pharmacol Sin; 2010 Sep; 31(9):1189-97. PubMed ID: 20729870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biological characterization of SN32976, a selective inhibitor of PI3K and mTOR with preferential activity to PI3Kα, in comparison to established pan PI3K inhibitors.
    Rewcastle GW; Kolekar S; Buchanan CM; Gamage SA; Giddens AC; Tsang KY; Kendall JD; Singh R; Lee WJ; Smith GC; Han W; Matthews DJ; Denny WA; Shepherd PR; Jamieson SMF
    Oncotarget; 2017 Jul; 8(29):47725-47740. PubMed ID: 28537878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical analysis of tasidotin HCl in Ewing's sarcoma, rhabdomyosarcoma, synovial sarcoma, and osteosarcoma.
    Garg V; Zhang W; Gidwani P; Kim M; Kolb EA
    Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5446-54. PubMed ID: 17875774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of common chromosomal translocations in small round blue cell pediatric tumors.
    Ponce-Castañeda MV; García-Chéquer AJ; Eguía Aguilar P; Abundes-Ramírez MA; Hernández-Angeles A; Nieto-Martínez K; Gómez-Laguna L; Sadowinski-Pine S; Cabrera-Muñoz Mde L
    Arch Med Res; 2014 Feb; 45(2):143-51. PubMed ID: 24486246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigation of IGF2, Hedgehog and fusion gene expression profiles in pediatric sarcomas.
    de Souza RR; Oliveira ID; del Giúdice Paniago M; Yaoita FH; Caran EM; Macedo CR; Petrilli AS; Abib Sde C; de Seixas Alves MT; de Toledo SR
    Growth Horm IGF Res; 2014 Aug; 24(4):130-6. PubMed ID: 24846856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synovial sarcoma is a stem cell malignancy.
    Naka N; Takenaka S; Araki N; Miwa T; Hashimoto N; Yoshioka K; Joyama S; Hamada K; Tsukamoto Y; Tomita Y; Ueda T; Yoshikawa H; Itoh K
    Stem Cells; 2010 Jul; 28(7):1119-31. PubMed ID: 20518020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SS18-SSX, the Oncogenic Fusion Protein in Synovial Sarcoma, Is a Cellular Context-Dependent Epigenetic Modifier.
    Tamaki S; Fukuta M; Sekiguchi K; Jin Y; Nagata S; Hayakawa K; Hineno S; Okamoto T; Watanabe M; Woltjen K; Ikeya M; Kato T; Toguchida J
    PLoS One; 2015; 10(11):e0142991. PubMed ID: 26571495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiangiogenic effect of ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor.
    Kong D; Okamura M; Yoshimi H; Yamori T
    Eur J Cancer; 2009 Mar; 45(5):857-65. PubMed ID: 19144509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition profiles of phosphatidylinositol 3-kinase inhibitors against PI3K superfamily and human cancer cell line panel JFCR39.
    Kong D; Dan S; Yamazaki K; Yamori T
    Eur J Cancer; 2010 Apr; 46(6):1111-21. PubMed ID: 20129775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In Vitro Antileukemia Activity of ZSTK474 on K562 and Multidrug Resistant K562/A02 Cells.
    Zhou Q; Chen Y; Chen X; Zhao W; Zhong Y; Wang R; Jin M; Qiu Y; Kong D
    Int J Biol Sci; 2016; 12(6):631-8. PubMed ID: 27194941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ZSTK474, a specific class I phosphatidylinositol 3-kinase inhibitor, induces G1 arrest and autophagy in human breast cancer MCF-7 cells.
    Wang Y; Liu J; Qiu Y; Jin M; Chen X; Fan G; Wang R; Kong D
    Oncotarget; 2016 Apr; 7(15):19897-909. PubMed ID: 26918351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Divergent patterns of telomere maintenance mechanisms among human sarcomas: sharply contrasting prevalence of the alternative lengthening of telomeres mechanism in Ewing's sarcomas and osteosarcomas.
    Ulaner GA; Hoffman AR; Otero J; Huang HY; Zhao Z; Mazumdar M; Gorlick R; Meyers P; Healey JH; Ladanyi M
    Genes Chromosomes Cancer; 2004 Oct; 41(2):155-62. PubMed ID: 15287028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.